Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR.

Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12.

PMID:
29440171
2.

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.

Alvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, Rimm DL, McMahon G, LaVallee TM.

PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017.

3.

Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.

Garton AJ, Seibel S, Lopresti-Morrow L, Crew L, Janson N, Mandiyan S, Trombetta ES, Pankratz S, LaVallee TM, Gedrich R.

Mol Cancer Ther. 2017 Apr;16(4):671-680. doi: 10.1158/1535-7163.MCT-16-0676. Epub 2017 Jan 30.

4.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.

Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.

5.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R.

Clin Cancer Res. 2017 May 15;23(10):2565-2574. doi: 10.1158/1078-0432.CCR-16-2152. Epub 2016 Nov 4.

6.

Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.

Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP.

Immunotherapy. 2016 Jun;8(7):767-74. doi: 10.2217/imt-2016-0040. Review.

PMID:
27349976
7.

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.

LaVallee TM, Alvarado D, Garton AJ, Trombetta ES, Gedrich R, McMahon G.

Crit Rev Oncog. 2015;20(5-6):485-508. doi: 10.1615/CritRevOncog.v20.i5-6.170. Review.

PMID:
27279243
8.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P.

Clin Cancer Res. 2014 Sep 15;20(18):4747-57. doi: 10.1158/1078-0432.CCR-14-0114. Epub 2014 Jul 14. Erratum in: Clin Cancer Res. 2014 Dec 1;20(23):6224. Huang, Jaiqi [corrected to Huang, Jiaqi].

9.

Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study.

Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, Yao Y, Lechleider RJ, Sikorski RS, Buzoianu M, Zhang J, Shi X, Richman LK, Lavallee TM.

PLoS One. 2013 Aug 21;8(8):e58557. doi: 10.1371/journal.pone.0058557. eCollection 2013.

10.

Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.

Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L.

J Pharm Sci. 2013 Jan;102(1):250-61. doi: 10.1002/jps.23343. Epub 2012 Oct 22.

PMID:
23090886
11.

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.

Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10.

PMID:
22327175
12.

CD22 as a target for cancer therapy.

Tu X, LaVallee T, Lechleider R.

J Exp Ther Oncol. 2011;9(3):241-8. Review.

PMID:
22070056
13.

Altered expression of insulin receptor isoforms in breast cancer.

Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, Boutrin A, Zhu W, Brohawn P, Chang Y, Viner J, LaVallee T, Richman L, Jallal B, Yao Y.

PLoS One. 2011;6(10):e26177. doi: 10.1371/journal.pone.0026177. Epub 2011 Oct 26.

14.

The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression.

Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, Leandro-García LJ, Rodríguez-Antona C, Snyder JP, Lavallee TM, Giannakakou P.

Cell Cycle. 2009 Dec;8(23):3914-24. Epub 2009 Dec 16.

PMID:
19901556
15.

Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.

Suwandi LS, Agoston GE, Shah JH, Hanson AD, Zhan XH, Lavallee TM, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6459-62. doi: 10.1016/j.bmcl.2009.09.009. Epub 2009 Sep 9.

PMID:
19782568
16.

Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Suwandi L, Hanson AD, Zhan X, LaVallee TM, Pribluda V, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6241-4. doi: 10.1016/j.bmcl.2009.08.020. Epub 2009 Aug 8.

PMID:
19782564
17.

Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.

Shah JH, Agoston GE, Suwandi L, Hunsucker K, Pribluda V, Zhan XH, Swartz GM, LaVallee TM, Treston AM.

Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. doi: 10.1016/j.bmc.2009.08.038. Epub 2009 Aug 21.

PMID:
19762246
18.

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM.

Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107.

19.

Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia.

Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, Shaked Y, Kerbel R, Lavallee T, Semenza GL.

Circ Res. 2007 Dec 7;101(12):1310-8. Epub 2007 Oct 11.

PMID:
17932327
20.

Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Lavallee TM, Zhan X, Pribluda VS, Treston AM.

Bioorg Med Chem. 2007 Dec 15;15(24):7524-37. Epub 2007 Sep 14.

PMID:
17910916
21.

Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.

Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H.

Cancer Res. 2006 Dec 15;66(24):11991-7.

22.

2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice.

Huh JI, Qiu TH, Chandramouli GV, Charles R, Wiench M, Hager GL, Catena R, Calvo A, LaVallee TM, Desprez PY, Green JE.

Endocrinology. 2007 Mar;148(3):1266-77. Epub 2006 Dec 7.

PMID:
17158205
23.

Honouring Jordan: Putting First Nations children first and funding fights second.

Lavallee TL.

Paediatr Child Health. 2005 Nov;10(9):527-9. No abstract available.

24.

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr.

Cancer Res. 2005 Oct 15;65(20):9406-14.

25.

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P.

Cancer Cell. 2003 Apr;3(4):363-75.

26.

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS.

Cancer Res. 2003 Jan 15;63(2):468-75.

27.

2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.

LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS.

Cancer Res. 2002 Jul 1;62(13):3691-7.

28.

2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.

Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ.

Cancer Metastasis Rev. 2000;19(1-2):173-9. Review.

PMID:
11191057
29.

S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro.

Mouta Carreira C, LaVallee TM, Tarantini F, Jackson A, Lathrop JT, Hampton B, Burgess WH, Maciag T.

J Biol Chem. 1998 Aug 28;273(35):22224-31.

30.

Synaptotagmin-1 is required for fibroblast growth factor-1 release.

LaVallee TM, Tarantini F, Gamble S, Mouta Carreira C, Jackson A, Maciag T.

J Biol Chem. 1998 Aug 28;273(35):22217-23.

31.

The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to heat shock.

Tarantini F, LaVallee T, Jackson A, Gamble S, Mouta Carreira C, Garfinkel S, Burgess WH, Maciag T.

J Biol Chem. 1998 Aug 28;273(35):22209-16.

32.
33.

Supplemental Content

Loading ...
Support Center